Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (r/mCC): Phase 1b/2 ENGOT-cx8/GOG-3024/ innovaTV 205 study dose-escalation results Meeting Abstract
| Authors: | Monk, B.; Van Gorp, T.; Lorusso, D.; O'Cearbhaill, R. E.; Westermann, A.; Banerjee, S.; Collins, D.; Klat, J.; Madsen, K.; Baurain, J. F.; Jackson, A.; Boere, I.; Pignata, S.; Gort, E.; Moroney, J.; Soumaoro, I.; Andreassen, C. M.; Nicacio, L.; Gennigens, C.; Vergote, I. |
| Abstract Title: | Tisotumab vedotin (TV) + bevacizumab or pembrolizumab or carboplatin in recurrent/metastatic cervical cancer (r/mCC): Phase 1b/2 ENGOT-cx8/GOG-3024/ innovaTV 205 study dose-escalation results |
| Meeting Title: | IGCS 2021 Annual Meeting |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 31 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2021 Aug 30-Sep 2 |
| Meeting Location: | Virtual |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2021-11-01 |
| Start Page: | A7 |
| End Page: | A8 |
| Language: | English |
| ACCESSION: | WOS:000773625600014 |
| DOI: | 10.1136/ijgc-2021-IGCS.13 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: O013/#573 -- Source: Wos |
